Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
October 27 2023 - 7:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced that it will host a conference
call and webcast on Friday, November 3, 2023, at 8:00
a.m. ET to discuss results for the third quarter 2023 and to
provide a corporate update.
To access the conference call:
- U.S. callers should dial +1-877-407-0989 and international
callers should dial +1-201-389-0921 approximately five minutes
before the call begins.
- Participants should ask to be connected to the Editas Medicine
Earnings Conference Call.
The conference call will also be webcast and can be
accessed from the “Investors” section of the Editas Medicine
website at https://www.editasmedicine.com. A replay will be
available at the same site approximately one hour after the
completion of the call.
In addition to the conference call, management will
participate in the following upcoming investor conferences:
- Stifel 2023 Healthcare ConferenceFormat:
Fireside ChatDate: Tuesday, November 14, 2023Time: 1:50
p.m. ETLocation: New York, NY
- Evercore ISI's Annual HealthCONx
ConferenceFormat: Fireside ChatDate: Tuesday, November 28,
2023Time: 1:20 p.m. ETLocation: Miami, FL
To access the live webcasts of Editas Medicine’s
presentations, please visit the “Investors” section of the
Company’s website at www.editasmedicine.com. An archived
replay will be available for approximately 30 days following each
event.
About Editas
MedicineAs a clinical-stage genome editing company, Editas
Medicine is focused on translating the power and potential of the
CRISPR/Cas12a and Cas9 genome editing systems into a robust
pipeline of treatments for people living with serious diseases
around the world. Editas Medicine aims to discover, develop,
manufacture, and commercialize transformative, durable, precision
genomic medicines for a broad class of diseases. Editas Medicine is
the exclusive licensee of Broad Institute’s Cas12a patent estate
and Broad Institute and Harvard University’s Cas9 patent estates
for human medicines. For the latest information and scientific
presentations, please visit www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2024 to May 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From May 2023 to May 2024